Boulder, Colorado-based Ambrosia Biosciences Inc. has closed an oversubscribed USD 100 million Series B financing round to advance its oral small molecule GLP-1 candidate and broader cardiometabolic pipeline toward clinical development.
The round was co-led by new investors Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, alongside new entrants Janus Henderson Investors, Samsara BioCapital, and one undisclosed institutional investor. The company said proceeds will fund initiation of a Phase I clinical trial for its lead GLP-1 receptor agonist program, with remaining capital supporting continued preclinical development of its GIP and amylin receptor programs.
Ambrosia is developing a portfolio of orally bioavailable small molecules targeting metabolic G-protein coupled receptors, including GLP-1, GIP, and amylin receptors. The company combines cryo-EM structural biology with computational chemistry and AI-driven molecular design to generate candidates intended for use both as standalone therapies and in combination regimens for obesity and related cardiometabolic diseases. The lead GLP-1 program targets the same receptor as semaglutide but is designed as a true small molecule engaging a transmembrane allosteric binding site, distinct from the extracellular domain where peptide hormones bind. The company said its approach is intended to deliver differentiated pharmacology relative to first-generation oral GLP-1 formulations such as oral semaglutide, which relies on peptide reformulation rather than a discrete small molecule scaffold.